|
|
| | SAR-20347 Basic information |
| Product Name: | SAR-20347 | | Synonyms: | SAR-20347;CPDD1211;2-(2-chloro-6-fluorophenyl)-5-((4-(morpholine-4-carbonyl)phenyl)amino)oxazole-4-carboxamide;2-(2-chloro-6-fluorophenyl)-5-({4-[(morpholin-4-yl)carbonyl]phenyl}amino)-1,3-oxazole-4-carboxylic acid amide;CS-2527;SAR-20347;SAR 20347;SAR20347;4-Oxazolecarboxamide, 2-(2-chloro-6-fluorophenyl)-5-[[4-(4-morpholinylcarbonyl)phenyl]amino]-;inhibit,SAR 20347,Janus kinase,JAK,SAR-20347,Inhibitor | | CAS: | 1450881-55-6 | | MF: | C21H18ClFN4O4 | | MW: | 444.84 | | EINECS: | | | Product Categories: | JAK1 & TYK2 | | Mol File: | 1450881-55-6.mol |  |
| | SAR-20347 Chemical Properties |
| Boiling point | 698.3±65.0 °C(Predicted) | | density | 1.445±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:94.5(Max Conc. mg/mL);212.43(Max Conc. mM) | | form | A solid | | pka | 13.97±0.50(Predicted) | | color | Light yellow to yellow |
| | SAR-20347 Usage And Synthesis |
| Uses | SAR-20347 is a small molecule inhibitor with specificity for JAK1 and tyrosine kinase 2 (TYK2). | | Biochem/physiol Actions | SAR-20347 is an orally active, ATP-competitive, TYK2- and JAK1-selective tyrosine kinase inhibitor (IC50 = 13 nM/TYK2 & 59 nM/JAK1 vs. 0.88 μM/JAK2 & 1.44 μM/JAK3 with 10 μM ATP) that effectively inhibits cellular TYK2- (IL12-induced pSTAT4 IC50 = 107 nM/CD4+ cells, 126 nM/NK-92) and JAK1- (IL6-induced pSTAT3 IC50 = 345 nM/TF-1, 407 nM/CD14+ cells) mediated signaling with little affinity toward 72 other kinases. SAR-20347 suppresses IL22-induced serum amyloid A (by 44%; 50 mg/kg p.o. 30 min prior to 10 μg IL22 i.p.) and alleviates imiquimod-induced psoriasis-like dermatitis (30 min prior and 5 h post daily 62.5 mg 5% imiquimod cream) in mice in vivo. |
| | SAR-20347 Preparation Products And Raw materials |
|